ReviewCurrent oncology (Toronto, Ont.)2021
Neoadjuvant Therapy in Lung Cancer: What Is Most Important: Objective Response Rate or Major Pathological Response?
Review in Current oncology (Toronto, Ont.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 19 citations in OpenAlex.
- Efficacy and safety of sintilimab-based neoadjuvant regimens in patients with resectable gastric or gastroesophageal junction adenocarcinoma: a single-arm systematic review and meta-analysis.Journal of gastrointestinal oncology · 2026Article
- A narrative review of pathologic response in non-small cell lung cancer: challenges, implications, and future directions.Translational lung cancer research · 2025Review
- Evaluating the efficacy of neoadjuvant immunotherapy combined with chemotherapy for stage IIIa non-small cell lung cancer.Scientific reports · 2025Article
- Surgical consensus for screening, diagnosis, staging, multimodal management and surveillance of early-stage resectable non-small cell lung cancer (NSCLC) in Malaysia.Translational lung cancer research · 2025Review
- The importance of histology in patient selection for platinum-based neoadjuvant treatment in non-small cell lung cancer.Turk gogus kalp damar cerrahisi dergisi · 2025Article
- Advances in Multimodal Imaging Techniques for Evaluating and Predicting the Efficacy of Immunotherapy for NSCLC.Cancer management and research · 2025Review
- A Single-Center Experience in Combined Oncological-Surgical Treatment for Resectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC).Diseases (Basel, Switzerland) · 2024Article
- [Modern individualized diagnostics and treatment of non-small cell lung cancer].Chirurgie (Heidelberg, Germany) · 2024Review
- Prognostic significance of T lymphocyte subgroups (CD4 and CD8) in lung cancer patients after neoadjuvant chemotherapy.Journal of cardiothoracic surgery · 2024Article
- Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023Review
- Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB-III non-small cell lung cancer patients using radiomic features.Thoracic cancer · 2023Article
- Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer.Frontiers in oncology · 2023Article
- Dynamic radiomics for predicting the efficacy of antiangiogenic therapy in colorectal liver metastases.Frontiers in oncology · 2023Article
- Treatments for Non-Small-Cell Lung Cancer: The Multiple Options for Precision Medicine.Current oncology (Toronto, Ont.) · 2022Article
- Review
- Review
- Integrated spatial analysis of gene mutation and gene expression for understanding tumor diversity in formalin-fixed paraffin-embedded lung adenocarcinoma.Frontiers in oncology · 2022Article
- Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the most fatal and frequently diagnosed malignant tumor. Neoadjuvant therapy is a promising approach for prolonging survival and increasing the chance of cure rates for patients with potentially resectable disease. Currently, many therapeutic alternatives, including chemotherapy, targeted therapy, and immunotherapy, are continually being explored to enrich the content of neoadjuvant therapy. However, neoadjuvant therapy remains to have no unified evaluation standards. Overall survival (OS) is the "gold standard" for evaluating the clinical benefit of cancer treatment, but it needs years for a reliable evaluation. Hence, researchers need to identify surrogate endpoints that can predict OS accurately and reliably without long follow-up periods. In this review, we describe the research progress of different neoadjuvant therapies and explore their response evaluation, aiming to identify stronger predictors of OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.